
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is a biotech company with a high chance of approval for their drug to treat mood and psychiatric disorders. With a market opportunity of $1.7 billion and strong earnings, the company has a clear path for success. Despite challenges in manufacturing and potential competition, their lead drug, COMP360, has shown promising results and the FDA's acceptance of their approach bodes well for future success.
Bears say
Compass Pathways is facing significant challenges in its path to regulatory approval and commercial launch. These challenges include the complex and potentially lengthy regulatory process for psychedelics, the need for additional infrastructure for commercialization, and the risk of losing exclusivity after 2034. Additionally, the company may face ESG considerations and regulatory challenges in the future due to the controversial nature of their therapy. While there is potential upside if their therapy is successfully approved and launched, there are also significant risks and uncertainties that may hinder the company's growth and impact their financials, making it a risky investment.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares